Company Profile
Shin Nippon Biomedical Laboratories (SNBL Japan), was founded in Kagoshima as Japan’s first contract research organization in 1957.
Since then, SNBL has steadily expanded and innovated to become a global business that works in the pre-clinical research, clinical pharmacology research, pharmacokinetics and analysis, clinical trial, site management organization (SMO), and other industries.
In recent years, we have built strong partnerships based on our corporate philosophy, including with our translational research business partner.
SNBL is striving toward globalization and expanded from Japan into North America, Europe, and other parts of Asia.
"At SNBL Group we are all committed to freeing patients from suffering, by supporting drug development and improving medical technology."
SNBL Group leverages its considerable experience and continues to provide service that is highly regarded for its responsiveness and high quality. We aim to surpass the expectations of all stakeholders.
|
Company name |
Shin Nihon Kagaku, Ltd. |
||||||
|
English Company name |
Shin Nippon Biomedical Laboratories, Ltd. (SNBL) |
||||||
|
Established |
September 16, 1957 |
||||||
|
Representative |
Representative Chairman, President & CEO Ryoichi Nagata |
||||||
|
Capital |
9billion 679million 70thousand 400 yen (as of June 30, 2016) |
||||||
|
Employees |
（as of September 2017） |
||||||
|
Type of Business |
Preclinical: Contracted pre-clinical and analysis studies |
||||||
|
Main Financers |
Kagoshima Bank, Mizuho Bank, Bank of Tokyo-Mitsubishi UFJ Shoko Chukin Bank |
||||||
|
Business Names |
Shin Nippon Biomedical Laboratories SMO, Ltd.
Shin Nippon Biomedical Laboratories Facilities, Ltd. |